Pharming Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Pharming Group NV
PHAR Stock  USD 21.18  0.78  3.82%   
Pharming Group's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pharming Group's valuation are provided below:
Gross Profit
325.7 M
Profit Margin
0.0011
Market Capitalization
1.5 B
Enterprise Value Revenue
3.8101
Revenue
362.3 M
There are over one hundred nineteen available trending fundamental ratios for Pharming Group NV, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check out Pharming Group's recent fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/28/2026, Enterprise Value is likely to grow to about 654.8 M, while Market Cap is likely to drop slightly above 296.6 M.

Pharming Group Total Revenue

358.87 Million

Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.4 M, Interest Expense of 6.8 M or Selling And Marketing Expenses of 6.1 M, as well as many indicators such as Price To Sales Ratio of 2.43, Dividend Yield of 0.0 or PTB Ratio of 3.82. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
Build AI portfolio with Pharming Stock
Check out the analysis of Pharming Group Correlation against competitors.

Pharming Group Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets483 M460 M239.7 M
Slightly volatile
Short and Long Term Debt Total69.8 M129.2 M75.5 M
Slightly volatile
Other Current Liabilities64.3 M61.2 M31.3 M
Slightly volatile
Total Current Liabilities47.5 M84.9 M51 M
Slightly volatile
Property Plant And Equipment Net15.6 M26.8 M16.5 M
Slightly volatile
Accounts Payable10.8 M11.6 M9.4 M
Slightly volatile
Cash69 M63.2 M71.5 M
Slightly volatile
Non Current Assets Total74.7 M139.8 M81.1 M
Slightly volatile
Non Currrent Assets Other3 M2.8 M3.5 M
Pretty Stable
Cash And Short Term Investments202.7 M193.1 M103 M
Slightly volatile
Net Receivables60.6 M57.7 M21.3 M
Slightly volatile
Common Stock Shares Outstanding46.1 M79.3 M56.2 M
Slightly volatile
Liabilities And Stockholders Equity483 M460 M239.7 M
Slightly volatile
Non Current Liabilities Total70.3 M120.9 M74.7 M
Slightly volatile
Inventory67.3 M64.1 M27.3 M
Slightly volatile
Other Current Assets3.9 M4.2 M3.4 M
Pretty Stable
Other Stockholder Equity393.9 M562.3 M394.1 M
Slightly volatile
Total Liabilities117.8 M205.8 M125.7 M
Slightly volatile
Total Current Assets336.2 M320.2 M154.4 M
Slightly volatile
Short Term Debt15.1 M8.3 M12.1 M
Pretty Stable
Intangible Assets41 M70.2 M44.1 M
Slightly volatile
Common Stock6.6 M7 M10.4 M
Slightly volatile
Other Liabilities124.8 K131.4 K17 M
Slightly volatile
Capital Lease Obligations17.9 M34.4 M11 M
Slightly volatile
Deferred Long Term Liabilities227.4 K239.4 K2.4 M
Slightly volatile
Net Invested Capital268.1 M349 M192 M
Slightly volatile
Short and Long Term Debt3.6 M3.8 M16.2 M
Slightly volatile
Non Current Liabilities Other124.8 K131.4 K16.3 M
Slightly volatile
Net Working Capital145.6 M235.3 M96.9 M
Slightly volatile
Property Plant Equipment47.3 M45 M20.3 M
Slightly volatile
Capital Stock8.2 M8.9 M7.4 M
Slightly volatile
Long Term Investments8.1 M4.9 M6.3 M
Slightly volatile
Property Plant And Equipment Gross47.3 M62.2 M37.6 M
Slightly volatile

Pharming Group Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense6.8 M10 M6.8 M
Slightly volatile
Selling And Marketing Expenses6.1 M6.4 M12.9 M
Pretty Stable
Total Revenue358.9 M341.8 M140.8 M
Slightly volatile
Other Operating Expenses369.3 M351.7 M134.2 M
Slightly volatile
Research Development100.4 M95.6 M41.8 M
Slightly volatile
Cost Of Revenue42.7 M40.7 M17.8 M
Slightly volatile
Total Operating Expenses326.5 M311 M116.4 M
Slightly volatile
Selling General Administrative111.2 M105.9 M33.7 M
Slightly volatile
Interest Income3.1 M5.6 M1.9 M
Slightly volatile
Reconciled Depreciation11.6 M18.5 M8.1 M
Slightly volatile

Pharming Group Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.6 M12.9 M6.2 M
Slightly volatile
Begin Period Cash Flow69.5 M71 M72.3 M
Slightly volatile
Depreciation19.4 M18.5 M7.9 M
Slightly volatile
Capital Expenditures869.6 K915.4 K4.8 M
Pretty Stable
End Period Cash Flow71.4 M63.2 M74.4 M
Slightly volatile
Issuance Of Capital Stock4 M2.1 M7.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.432.5654.1056
Slightly volatile
Days Sales Outstanding12770.89114
Slightly volatile
Average Payables6.4 M9.3 M7.2 M
Slightly volatile
Stock Based Compensation To Revenue0.04130.04350.2258
Slightly volatile
Capex To Depreciation0.05370.05651.3333
Slightly volatile
EV To Sales2.642.7851.8435
Slightly volatile
Inventory Turnover0.910.920.8132
Very volatile
Days Of Inventory On Hand500526695
Pretty Stable
Payables Turnover4.163.962.6032
Slightly volatile
Sales General And Administrative To Revenue0.350.371.3994
Slightly volatile
Average Inventory11.8 M21.8 M17.5 M
Slightly volatile
Research And Ddevelopement To Revenue0.280.292.0749
Slightly volatile
Capex To Revenue0.00290.00310.1841
Slightly volatile
Cash Per Share0.260.270.2901
Slightly volatile
Days Payables Outstanding90.6295.39261
Slightly volatile
Income Quality0.140.15831.0518
Pretty Stable
Intangibles To Total Assets0.210.180.1691
Slightly volatile
Current Ratio2.283.282.8153
Slightly volatile
Receivables Turnover9.746.818.7852
Very volatile
Capex Per Share0.00120.00130.0136
Slightly volatile
Average Receivables43 M41 M17.2 M
Slightly volatile
Revenue Per Share0.390.370.1875
Slightly volatile
Interest Debt Per Share0.190.20.1263
Slightly volatile
Debt To Assets0.220.250.2691
Slightly volatile
Graham Number0.370.330.2972
Slightly volatile
Operating Cycle567597805
Slightly volatile
Days Of Payables Outstanding90.6295.39261
Slightly volatile
Long Term Debt To Capitalization0.460.30.3681
Slightly volatile
Quick Ratio1.82.622.264
Slightly volatile
Net Income Per E B T1.161.222.6064
Very volatile
Cash Ratio0.610.651.5205
Very volatile
Days Of Inventory Outstanding500526695
Pretty Stable
Days Of Sales Outstanding12770.89114
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.661.025
Pretty Stable
Fixed Asset Turnover11.6311.086.6923
Slightly volatile
Debt Ratio0.220.250.2691
Slightly volatile
Price Sales Ratio2.432.5654.1056
Slightly volatile
Asset Turnover0.70.670.4548
Slightly volatile

Pharming Group Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap296.6 M573.7 M516.5 M
Slightly volatile
Enterprise Value654.8 M623.6 M537.8 M
Slightly volatile

Pharming Fundamental Market Drivers

Forward Price Earnings57.1429
Cash And Short Term Investments167.9 M

Pharming Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-64.7 K-61.4 K
Total Revenue341.8 M358.9 M
Cost Of Revenue40.7 M42.7 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.37  0.35 
Research And Ddevelopement To Revenue 0.29  0.28 
Revenue Per Share 0.37  0.39 
Ebit Per Revenue(0.01)(0.01)

Pair Trading with Pharming Group

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharming Group position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharming Group will appreciate offsetting losses from the drop in the long position's value.

Moving together with Pharming Stock

  0.64VNDA Vanda PharmaceuticalsPairCorr
  0.79HLN Haleon plcPairCorr

Moving against Pharming Stock

  0.79REVB Revelation BiosciencesPairCorr
  0.72SLN Silence Therapeutics PLC Downward RallyPairCorr
  0.68VYGR Voyager TherapeuticsPairCorr
  0.67VINC Vincerx Pharma CommonPairCorr
  0.66DRMA Dermata TherapeuticsPairCorr
The ability to find closely correlated positions to Pharming Group could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharming Group when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharming Group - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharming Group NV to buy it.
The correlation of Pharming Group is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharming Group moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharming Group NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pharming Group can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY